Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GnRH antagonist + methyltestosterone is a combination therapy that works through complementary mechanisms. GnRH antagonists competitively bind to GnRH receptors in the pituitary gland, preventing native GnRH from binding and thereby suppressing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased testosterone production. Methyltestosterone is an anabolic steroid hormone that supplements testosterone levels. This combination allows for hormonal suppression while maintaining sufficient testosterone levels to prevent side effects like decreased libido. The combination has been studied as a potential male contraceptive approach and for treating certain hormone-dependent conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GnRH antagonist + methyltestosterone.